Nature Communications (Apr 2024)

Discovery of a small-molecule inhibitor that traps Polθ on DNA and synergizes with PARP inhibitors

  • William Fried,
  • Mrityunjay Tyagi,
  • Leonid Minakhin,
  • Gurushankar Chandramouly,
  • Taylor Tredinnick,
  • Mercy Ramanjulu,
  • William Auerbacher,
  • Marissa Calbert,
  • Timur Rusanov,
  • Trung Hoang,
  • Nikita Borisonnik,
  • Robert Betsch,
  • John J. Krais,
  • Yifan Wang,
  • Umeshkumar M. Vekariya,
  • John Gordon,
  • George Morton,
  • Tatiana Kent,
  • Tomasz Skorski,
  • Neil Johnson,
  • Wayne Childers,
  • Xiaojiang S. Chen,
  • Richard T. Pomerantz

DOI
https://doi.org/10.1038/s41467-024-46593-1
Journal volume & issue
Vol. 15, no. 1
pp. 1 – 15

Abstract

Read online

Abstract The DNA damage response (DDR) protein DNA Polymerase θ (Polθ) is synthetic lethal with homologous recombination (HR) factors and is therefore a promising drug target in BRCA1/2 mutant cancers. We discover an allosteric Polθ inhibitor (Polθi) class with 4–6 nM IC50 that selectively kills HR-deficient cells and acts synergistically with PARP inhibitors (PARPi) in multiple genetic backgrounds. X-ray crystallography and biochemistry reveal that Polθi selectively inhibits Polθ polymerase (Polθ-pol) in the closed conformation on B-form DNA/DNA via an induced fit mechanism. In contrast, Polθi fails to inhibit Polθ-pol catalytic activity on A-form DNA/RNA in which the enzyme binds in the open configuration. Remarkably, Polθi binding to the Polθ-pol:DNA/DNA closed complex traps the polymerase on DNA for more than forty minutes which elucidates the inhibitory mechanism of action. These data reveal a unique small-molecule DNA polymerase:DNA trapping mechanism that induces synthetic lethality in HR-deficient cells and potentiates the activity of PARPi.